Agilent Technologies Introduces CE-IVD Marked SureScan Dx Microarray Scanner for the European Market
SANTA CLARA, Calif., Feb. 27, 2013 Agilent Technologies Inc. (NYSE: A) today launched new SureScan Dx microarray scanner that is CE marked for in vitro diagnostic use in Europe.
(PressZoom) - SANTA CLARA, Calif., Feb. 27, 2013 Agilent Technologies Inc. (NYSE: A) today launched new SureScan Dx microarray scanner that is CE marked for in vitro diagnostic use in Europe.
The SureScan Dx microarray scanner is indicated for use in a clinical laboratory environment when measuring fluorescence signals of labeled DNA or RNA targets hybridized to microarrays used as part of a validated diagnostic assay. The system has been validated for use with Agilent comparative genomic hybridization and gene expression microarrays.
"The Agilent SureScan Dx microarray scanner delivers high sensitivity and resolution for copy number change analysis, as well as outstanding dynamic range, providing clinician's confidence in their microarray results," said Frdric Laget, vice president, Agilent's Global Genomics Field Organization. "As part of Agilent's extensive portfolio of genomics solutions, the IVD scanner offers clinical laboratories an instrument to enable development of microarray-based assays."
The SureScan Dx microarray scanner is CE marked in Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, and the United Kingdom.
"Agilent is the market leader in cytogenetic arrays and we are committed to bringing the best microarray solutions to a growing number of diagnostic labs and hospitals around the world," said Heidi Kijenski, director of clinical marketing, Agilent's Genomics Solutions Division. "The CE-marking aligns with our overall strategy to seek regulatory clearance in key geographies, including our intention to file for 510(k) clearance in the United States."
For more information on the Agilent SureScan Dx Microarray Scanner, visit www.agilent.com/genomics/SureScanDxSystem.
About Agilent in Genomics
Agilent is a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex target-enrichment systems enable researchers to easily choose which segments of a genome to sequence, avoiding the time and expense needed to sequence the entire genome. HaloPlex and its same-day sample-to-sequencer workflow is well suited for next-generation desktop sequencers, whereas SureSelect's ability to accurately capture whole exomes and whole methylomes in a single reaction pairs well with high-throughput next-generation sequencing systems. These are just two products arising from Agilent's expertise in synthesizing custom complex mixtures of long oligonucleotide gained in microarray manufacturing. Additional product lines built on this core technology include microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive oligonucleotide fluorescent in situ hybridization product line. In addition to oligonucleotide-based products, Agilent offers a microfluidic bioanalyzer to measure sample quality, a target-enrichment tool to speed next-generation sequencing, and a full set of reagents, hardware, methods and bioinformatics software for genomic experiments.
-------------------------------------------------------------------------------- About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.
This news item was released on 2013-03-01. Please make sure to visit the official company or organization web site to learn more about the original release date. See our disclaimer for more information.
(c) PressZoom.com - Press Release Distribution Service - All Rights Reserved